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the shoulder, intermediate and high dose ranges of the dose 
volume histogram until coverage was tight but not 
compromised by ICRU 83. Homogeneity index was calculated 
as (D2%-D98%)/D50%. Two-sided paired sample t-tests were 
used to assess statistical significance, taken as p 
Results: The mean volume prescribed 21 Gy was 398 cm3 
(range 259-611) for VMAT-conv and 318 cm3 (range 213-526) 
for VMAT-SIB plans. By using VMAT-SIB, 72-78% of the volume 
of the VB at the level of the kidneys was prescribed 15 Gy 
rather than 21 Gy. PTV minimum, mean, maximum, D2% and 
D98% doses did not differ significantly between the plans. 
Both techniques achieved clinically acceptable plans. As 
expected, VMAT-SIB plans had greater VB dose 
inhomogeneity. VMAT-SIB allowed reductions in some 
combined (right plus left) and contralateral kidney doses 
(Table 1). Contralateral kidney V15, V18 and V21, combined 
kidney V12, V15 and V18, and ipsilateral kidney and liver 
doses were similar. The renal sparing achieved in at least 3 of 
5 cases was judged to be clinically significant, most apparent 
at the 5 Gy level; contralateral kidney V5 was reduced from 
[24, 31, 95, 94, 81]% to [13, 6, 11, 20, 13]% in the 5 cases. An 
example is shown in Figure 1. 
 
 
 
 
 
Conclusions: Dose painting with VMAT-SIB for high risk 
abdominal neuroblastoma is feasible. Controlled dose 
inhomogeneity in the VB can improve contralateral kidney 
sparing without increasing expected risks of asymmetric 
growth. The absolute differences between the techniques 
can be small and work is ongoing to identify factors that 
predict patients most likely to benefit. The benefit of 
sizeable reductions in the volume of contralateral kidney 
receiving 5 Gy is not well described, but may be clinically 
significant. 
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Purpose/Objective: To retrospectively compare VMAT and 
IMRT for cranio-spinal irradiation (CSI) of standard-risk 
medulloblastoma (MB) paediatric patients and to estimate 
their impact on the potential clinical benefit.  
Materials and Methods: We selected 10 paediatric MB 
patients, with a median age of 7.5 years, who received CSI 
with a dose of 23.4 Gy, followed by a boost to posterior fossa 
up to 55.8 Gy, with 1.8 Gy/fraction. 
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Cranio-spinal CTV included the entire cranio-spinal axis; the 
related PTV was a uniform expansion of the CTV with a 
margin of 3 mm for brain and 7 mm for spinal cord. The boost 
CTV was the tumour bed; the boost PTV was generated by a 
margin of 3 mm. Organs-at-risk (OARs) were: the brain, eyes, 
lenses, optical nerves, optic chiasm, thyroid, pituitary, heart, 
lungs, liver, kidneys, and gonads. Non-target tissue was 
defined as the body outline excluding the PTVs and the OARs. 
For each patient, 2 treatment plans (cranio-spinal plus 
boost), VMAT and IMRT, were generated, using 6 MV photons 
and 2 isocenters at the same source-axis-distance and shifted 
apart according to patient's length. For VMAT 2 coplanar 
complete arcs, and for IMRT 5 coplanar beams evenly 
distributed were used for each isocenter.  
DVHs and treatment delivery data (MU and number of 
segments) from VMAT and IMRT plans were compared.  
Results: Fig. 1. Dose distribution comparison between VMAT 
(1a) and IMRT (1b), in axial and sagittal views (cranio-spinal 
plus boost). The dose is displayed as: orange: 53.01 Gy (95% 
of boost dose of 55.8 Gy), green: 22.23 Gy (95% of CSI dose of 
23.4 Gy), dark blue: 5 Gy.  
a. 
 
 
b. 
 
 
Table1. Dosimetric comparison between VMAT, IMRT and 
dose limits for paediatric patients.PTV: Planning-Target-
Volume; HI: homogeneity index HI = D2%/D98%; CI: 
conformity index. 
 
 
The low dose spread to non-target tissue was lower and 
statistically significant (p=0.00625) for VMAT plans (V5Gy of 
37.37% for VMAT vs. 40.69% for IMRT), and showed an inverse 
linear dependence with the patient antero-posterior 
diameter at xyphoid level. 
Fig. 2. Relation between non-target tissue V5Gy and patient 
antero-posterior diameter, for supine and prone positions.  
 
 
 
Analysis of treatment delivery data showed that IMRT plans 
had about 40% less MU than VMAT (p=0.00001).  
 
Conclusions: VMAT and IMRT produce similar dose 
distribution for CSI of paediatric patients.None of them was 
able to reduce the doses to eyes, lens, cochleas, pituitary 
and brain to the dose limits for paediatric patients. Thus, 
both carry similar increased risk of neurocognitive decline, 
growth, hearing loss, vision impairment and secondary 
malignancies. Further research is needed to assess the 
clinical benefit of novel radiotherapy modalities. 
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Purpose/Objective: Progressive diffuse intrinsic pontine 
glioma (DIPG) is a clinical challenge and the most common 
death cause among pediatric brain tumor patients. Recent 
reports of cases of progressive DIPG with re-irradiation have 
shown a better outcome than any other treatment modality. 
In our service, we have been performing re-irradiation of 
progressive DIPG patients since 2013. In order to evaluate the 
preliminary results of this treatment strategy, we have 
retrospectively reviewed patients' chart data. 
Materials and Methods: This is an observational retrospective 
evaluation of a small cohort of four cases of pediatric 
patients with progressive DIPG treated with re-iradiation 
after previous treatment with radiation therapy and 
chemotherapy. It has received approval by our institutional 
review board with a waiver of informed consent for these 
patients because they had already deceased. All patients 
were treated in our institution (Pediatric Cancer Center) and 
received radiation therapy (RT) at CRIO (Centro Regional 
Integrado de Oncologia) a partner institution. The authors 
were in charge of the treatment of the patients. This report 
complies with CARE guidelines for case reports.  
